Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan for non-alcoholic steatohepatitis
ACTRN12606000411549Phase 2Not yet recruiting
- Sponsor
- Professor Peter Angus
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of telmisartan in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Professor Peter Angus. Primary endpoint: Effect of AT1 receptor blockade with telmisartan on hepatic fibrogenesis in non-alcoholic steatohepatitis. Planned start Dec 2006; status: not yet recruiting.
02
Drugs
telmisartan
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on ACTRN12606000411549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000411549.